# A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab

> **NCT02173392** · PHASE1 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 145 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Brodalumab

## Key facts

- **NCT ID:** NCT02173392
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2014-11
- **Final completion:** 2014-12
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2017-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02173392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02173392, "A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02173392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*